Curis Reports Q4 Net Income, Secures Cash Runway to H2 2027 with $80.8M PIPE, and Updates on Clinical Progress
CRIS is trading near its 52-week low of $0.75 (0.9% above the low).
Summary
Curis reported Q4 2025 net income of $19.4 million, driven by a one-time gain, and announced a significant $80.8 million PIPE financing that extends its cash runway into the second half of 2027, alongside positive clinical updates for its emavusertib programs.
Key Events · Financing and Capital Events · CRIS
-
Strong Q4 2025 Financial Performance
Curis reported net income of $19.4 million ($1.23 per share) for Q4 2025, a significant improvement from a net loss in the prior year, primarily due to a $27.2 million non-cash gain from an asset sale.
-
Extended Cash Runway to H2 2027
The company announced that initial proceeds from a January 2026 PIPE financing, combined with potential warrant exercises, are expected to fund operations into the second half of 2027, providing critical financial stability.
-
Significant PIPE Financing Closed
Curis closed a private placement in January 2026 with initial gross proceeds of $20.2 million and warrants for up to an additional $60.6 million, totaling up to $80.8 million, with warrants exercisable at $0.75 per share.
-
Positive PCNSL Clinical Data
Updated clinical data for emavusertib in Primary CNS Lymphoma (PCNSL) showed a 100% objective response rate (ORR) in BTKi-naïve patients and 37% ORR in BTKi-experienced patients, with plans for accelerated approval filings.
Analysis · CRIS · Life Sciences
This 8-K filing is highly important for Curis, a life sciences company currently trading near its 52-week low. The company reported a significant swing to net income in Q4 2025, largely due to a one-time non-cash gain from an asset sale. More critically, the announcement of a substantial $80.8 million PIPE financing, with initial proceeds already received, provides a crucial extension of its cash runway into the second half of 2027. This financing, representing a massive capital injection relative to the company's market capitalization, significantly de-risks its near-term operations and addresses prior funding concerns. Concurrently, Curis delivered strong clinical updates, particularly for its emavusertib program in Primary CNS Lymphoma, showing a 100% objective response rate in a key patient subset and outlining plans for accelerated approval filings. These positive developments in both financing and clinical progress are vital for investor confidence and the company's strategic trajectory.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 41% of the 305 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRIS was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $0.75 to $3.13. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.